Coherus BioSciences Inc. [NASDAQ: CHRS] slipped around -0.65 points on Wednesday, while shares priced at $18.05 at the close of the session, down -3.48%. The company report on November 21, 2020 that Coherus BioSciences Announces New Employment Inducement Grants.
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), announced that effective November 19, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 140,500 shares of the common stock of the Company to 10 newly hired non-officer employees, with a per share exercise price of $17.92, the closing trading price on the grant date.
The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the Company’s board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company.
Coherus BioSciences Inc. stock is now 0.25% up from its year-to-date (YTD) trading value. CHRS Stock saw the intraday high of $18.79 and lowest of $17.91 per share. The company’s 52-week high price is 23.03, which means current price is +66.18% above from all time high which was touched on 02/20/20.
Compared to the average trading volume of 885.67K shares, CHRS reached a trading volume of 1082111 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Coherus BioSciences Inc. [CHRS]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CHRS shares is $29.90 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CHRS stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for Coherus BioSciences Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on July 16, 2020. While these analysts kept the previous recommendation, SunTrust raised their target price to Buy. The new note on the price target was released on April 17, 2020, representing the official price target for Coherus BioSciences Inc. stock. On August 02, 2019, analysts increased their price target for CHRS shares from 25 to 27.
The Average True Range (ATR) for Coherus BioSciences Inc. is set at 0.75, with the Price to Sales ratio for CHRS stock in the period of the last 12 months amounting to 2.62. The Price to Book ratio for the last quarter was 5.06, with the Price to Cash per share for the same quarter was set at 7.09. Price to Free Cash Flow for CHRS in the course of the last twelve months was 9.71 with Quick ratio for the last quarter at 5.20.
How has CHRS stock performed recently?
Coherus BioSciences Inc. [CHRS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.35. With this latest performance, CHRS shares gained by 1.23% in over the last four-week period, additionally sinking by -3.17% over the last 6 months – not to mention a rise of 1.75% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CHRS stock in for the last two-week period is set at 50.70, with the RSI for the last a single of trading hit 51.13, and the three-weeks RSI is set at 50.74 for Coherus BioSciences Inc. [CHRS]. The present Moving Average for the last 50 days of trading for this stock 17.95, while it was recorded at 18.27 for the last single week of trading, and 17.80 for the last 200 days.
Coherus BioSciences Inc. [CHRS]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Coherus BioSciences Inc. [CHRS] shares currently have an operating margin of +1.24 and a Gross Margin at +47.30. Coherus BioSciences Inc.’s Net Margin is presently recorded at -0.10.
Return on Total Capital for CHRS is now -0.36, given the latest momentum, and Return on Invested Capital for the company is -0.37. Return on Equity for this stock declined to -0.49, with Return on Assets sitting at -0.20. When it comes to the capital structure of this company, Coherus BioSciences Inc. [CHRS] has a Total Debt to Total Equity ratio set at 33.17. Additionally, CHRS Total Debt to Total Capital is recorded at 24.91, with Total Debt to Total Assets ending up at 13.59. Long-Term Debt to Equity for the company is recorded at 32.05, with the Long-Term Debt to Total Capital now at 24.07.
Reflecting on the efficiency of the workforce at the company, Coherus BioSciences Inc. [CHRS] managed to generate an average of -$88 per employee. Receivables Turnover for the company is 52.47 with a Total Asset Turnover recorded at a value of 1.95.Coherus BioSciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.20 and a Current Ratio set at 5.40.
Earnings analysis for Coherus BioSciences Inc. [CHRS]
With the latest financial reports released by the company, Coherus BioSciences Inc. posted 0.56/share EPS, while the average EPS was predicted by analysts to be reported at 0.72/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -22.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CHRS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Coherus BioSciences Inc. go to 2.20%.
Insider trade positions for Coherus BioSciences Inc. [CHRS]
There are presently around $1,551 million, in the hands of institutional investors. The top three institutional holders of CHRS stocks are: BLACKROCK INC. with ownership of 10,210,732, which is approximately -0.104% of the company’s market cap and around 0.50% of the total institutional ownership; TEMASEK HOLDINGS (PRIVATE) LTD, holding 7,381,116 shares of the stock with an approximate value of $133.23 million in CHRS stocks shares; and JPMORGAN CHASE & CO, currently with $85.38 million in CHRS stock with ownership of nearly 4.241% of the company’s market capitalization.
Positions in Coherus BioSciences Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 115 institutional holders increased their position in Coherus BioSciences Inc. [NASDAQ:CHRS] by around 8,638,322 shares. Additionally, 85 investors decreased positions by around 9,822,832 shares, while 24 investors held positions by with 67,458,908 shares. The mentioned changes placed institutional holdings at 85,920,062 shares, according to the latest SEC report filing. CHRS stock had 33 new institutional investments in for a total of 1,470,420 shares, while 25 institutional investors sold positions of 2,690,511 shares during the same period.